Eligibility for hepatitis B virus (HBV) treatment and prevalence of drug resistance in a Ugandan population cohort
While the WHO 2024 treatment criteria offer an opportunity to expand access to care, there is a need to determine how assessment tools differ in determination of eligibility in different settings. HBVDR remains uncommon but more research is needed to understand its prevalence and clinical impact in African populations.
Authors
- Ronald Makanga (ORCID: https://orcid.org/0009-0001-8430-8234)
- Moses Kwizera Mbonye
- Philippa Clare Matthews (ORCID: https://orcid.org/0000-0002-4036-4269)
- Sheila Lumley (ORCID: https://orcid.org/0000-0001-6825-9324)
- Anna McNaughton (ORCID: https://orcid.org/0000-0002-7436-8727)
- Richard Ndungutse
- Elizabeth Waddilove (ORCID: https://orcid.org/0000-0003-3228-3845)
- Beatrice Kimono
- Florence Nambaziira Muzaale
- Kevin Ojambo
- Chris Kent
- Brian Ssengendo
- Josh Quick
- Ponsiano Ocama
- Janet Seeley
- Joseph Mugisha
- Robert Newton
Institutions
- The Francis Crick Institute (GB)
- University of Bristol (GB)
- London School of Hygiene & Tropical Medicine (GB)
- Medawar Building for Pathogen Research (GB)
- Oxford University Hospitals NHS Trust (GB)
- University College London (GB)
- Makerere University (UG)
- University of Birmingham (GB)
- Uganda Virus Research Institute (UG)
Publication Details
- Journal
- Journal of Infection
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1016/j.jinf.2026.106682
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- London School of Hygiene and Tropical Medicine
- Wellcome Trust
- Medical Research Council